MedTrace Logo

Effects of Esketamine on Postpartum Depression

NCT05229913 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-02-08

No results posted yet for this study

Summary

Different concentrations of Esketamine were used after cesarean section. Through the evaluation of postoperative psychological status and analgesic effect, the optimal dosage of Esketamine to exert the effects of depression and analgesia was analyzed.

Conditions

Interventions

DRUG

Esketamine is not added

Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg

DRUG

Esketamine 0.2mg/kg

Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.

DRUG

Esketamine 0.4mg/kg

Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.

DRUG

Esketamine 0.6mg/kg

Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.

DRUG

Esketamine 0.8mg/kg

Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.

Sponsors & Collaborators

  • Qinghai Red Cross Hospital

    collaborator OTHER

  • Qinghai University

    lead OTHER

Principal Investigators

  • Wang Xuejun, director · Department of Anesthesiology, Qinghai Red Cross Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-20
Primary Completion
2022-09-30
Completion
2023-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229913 on ClinicalTrials.gov